News Former Seagen CEO Siegall pops up at new biotech Siegall resigned from Seagen last year amid claims of domestic abuse, though was not charged.
News Astellas GLOWing as Claudin drug aces gastric cancer trial Pair of positive phase 3 studies means company will file for approval of zolbetuximab soon.
News Could Daiichi Sankyo have another ADC winner in cancer? New data point to impressive efficacy in advanced EGFR-mutated non-small cell lung cancer.
News Merck suffers a setback in its TIGIT programme Missed endpoint in mid-stage study in lung cancer is a worry after other TIGIT failures.
News Servier’s $1.8bn Agios deal delivers glioma prospect IDH inhibitor vorasidenib could be practice changing in this form of brain cancer, says firm.
News Exscientia builds cancer pipeline with two BMS drugs LSD1 and MALT1 inhibitors inherited from BMS alliance will be biotech's next cancer candidates.
News Former Seagen CEO Siegall pops up at new biotech Siegall resigned from Seagen last year amid claims of domestic abuse, though was not charged.
R&D Sponsored An inside guide to unlocking clinical research in the UK An inside guide to unlocking clinical research in the UK
